Market Overview

Teva Prices Offering of $2B in Senior Notes

Related TEVA
Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca
Notable Hedge Funds Disclose Additions And Reductions To Holdings
Sofinnova Ventures Closes $500M Fund (Fox Business)

Teva Pharmaceutical Industries Limited (NYSE: TEVA) announced today that it successfully priced a debt offering by its special purpose finance subsidiaries, consisting of two tranches:

* $700,000,000 of 2.250% fixed rate senior notes maturing in March 2020 issued by Teva Pharmaceutical Finance IV, LLC; and * $1,300,000,000 of 2.950% fixed rate senior notes maturing in December 2022 issued by Teva Pharmaceutical Finance Company BV

The notes will be sold at a price of $999.55 and $998.02 per $1,000 principal amount, respectively, and are rated A3 by Moody's Investor Services, A- by Standard & Poor's and A- by Fitch Ratings. The notes will be guaranteed by Teva Pharmaceutical Industries Limited.

Teva intends to use the net proceeds from this offering to repay the approximately $700 million remaining outstanding under a term loan credit facility due in 2013 and 2014 and redeem the $1 billion outstanding principal amount of its 1.70% Senior Notes due November 2014 via a make-whole call. The balance will be used to repay other indebtedness and/or for general corporate purposes.

Posted-In: News Offerings

 

Related Articles (TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters